Kenalog-40 and Ocrevus

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using ocrelizumab together with triamcinolone may increase the risk of serious infections. Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and has taken appropriate precautions and is monitoring you closely for any potential complications. Contact your doctor immediately if you develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR: The use of the CD20-directed cytolytic antibody ocrelizumab with other immune-modulating or immunosuppressive therapy, including immunosuppressant doses of corticosteroids may increase the risk of infections. Ocrelizumab alone has been reported to increase the risk for upper and lower respiratory tract infections, skin infections, and herpes-related infections. Progressive Multifocal Leukoencephalopathy (PML) due to JC virus infection has also been reported with other anti-CD20 antibodies. However, in relapsing multiple sclerosis (RMS) clinical trials, ocrelizumab was not associated with an increased risk of serious infections, and no cases of PML were reported. Ocrelizumab has not been studied in combination with or Multiple Sclerosis therapies.

MANAGEMENT: The increased risk of additive immunosuppression should be considered if coadministering ocrelizumab with other immunosuppressive therapy. In addition, the prolonged immunosuppressant effects and mode of action of other immunosuppressant drugs such as daclizumab, fingolimod, natalizumab, teriflunomide, or mitoxantrone should be considered prior to starting ocrelizumab therapy. Patients should be advised to notify their doctor if they develop signs or symptoms of infection, including upper or lower respiratory tract infection, skin infection, herpes related infection, or PML.

Kenalog-40

Generic Name: triamcinolone

Brand name: Kenalog-40, Zilretta, Aristocort, Azmacort

Synonyms: Kenalog-40 (injection)

What is Kenalog-40?

Ocrevus

Generic Name: ocrelizumab

Brand name: Ocrevus

Synonyms: n.a.

What is Ocrevus?